ERBB2 and cancer: Using the “distal Cancer CREs”, we first examined the differences in the chromatin accessibility signatures of ER + /HER2 − and TNBC, and identified 4294 ER + /HER2 − CREs and 2123 TNBC CREs (log2FC > 1 and FDR < 0.01) (Fig. 3b).